{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:37Z","timestamp":1786975597380,"version":"build-2736575974"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2021,4,1]]},"DOI":"10.1001\/jamainternmed.2020.8441","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:32:35Z","timestamp":1613993555000},"page":"490","source":"Crossref","is-referenced-by-count":46,"title":["Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval"],"prefix":"10.1001","volume":"181","author":[{"given":"Avi","family":"Cherla","sequence":"first","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[{"name":"Department of Oncology and Department of Public Health Sciences, Division of Cancer Care and Epidemiology, Queen\u2019s University, Kingston, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Mossialos","sequence":"additional","affiliation":[{"name":"Department of Health Policy, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"ioi200111r2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ioi200111r3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"ioi200111r4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration.","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"key":"ioi200111r5","doi-asserted-by":"publisher","first-page":"m770","DOI":"10.1136\/bmj.m770","article-title":"Inappropriate use of progression-free survival in cancer drug approvals.","volume":"368","author":"Naci","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"ioi200111r6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses.","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"7","key":"ioi200111r7","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/ijc.v144.7","article-title":"Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials.","volume":"144","author":"Hwang","year":"2019","journal-title":"Int J Cancer"},{"issue":"24","key":"ioi200111r8","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMsa1200223","article-title":"Regulatory review of novel therapeutics\u2014comparison of three regulatory agencies.","volume":"366","author":"Downing","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"ioi200111r9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/cpt.v107.1","article-title":"A comparison of EMA and FDA decisions for new drug marketing applications 2014-2016: concordance, discordance, and why.","volume":"107","author":"Kashoki","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"ioi200111r12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ejim.2015.08.008","article-title":"Approvals of drugs with uncertain benefit-risk profiles in Europe.","volume":"26","author":"Banzi","year":"2015","journal-title":"Eur J Intern Med"},{"key":"ioi200111r13","doi-asserted-by":"publisher","first-page":"l266","DOI":"10.1136\/bmj.l266","article-title":"New agreement on branded drugs for the NHS.","volume":"364","author":"Naci","year":"2019","journal-title":"BMJ"},{"key":"ioi200111r14","doi-asserted-by":"publisher","first-page":"j5387","DOI":"10.1136\/bmj.j5387","article-title":"Accelerated access to new drugs and technologies.","volume":"359","author":"Naci","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"ioi200111r15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMp1705800","article-title":"The fate of FDA postapproval studies.","volume":"377","author":"Woloshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"ioi200111r16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1377\/hlthaff.2017.1553","article-title":"Specialty drug coverage varies across commercial health plans in the US.","volume":"37","author":"Chambers","year":"2018","journal-title":"Health Aff (Millwood)"},{"issue":"21","key":"ioi200111r17","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMp1700446","article-title":"Accelerated approval and expensive drugs\u2014a challenging combination.","volume":"376","author":"Gellad","year":"2017","journal-title":"N Engl J Med"},{"key":"ioi200111r18","first-page":"1","article-title":"NICE\u2019s evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances.","author":"Pinilla-Dominguez","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"ioi200111r19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/nrd.2016.81","article-title":"Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.","volume":"15","author":"Ciani","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"ioi200111r1","unstructured":"US Food and Drug Administration. Accelerated approval program. Updated October 26, 2020. Accessed January 31, 2020. https:\/\/www.fda.gov\/drugs\/information-healthcare-professionals-drugs\/accelerated-approval-program"},{"key":"ioi200111r10","unstructured":"European Medicines Agency website. Accessed January 31, 2020. https:\/\/www.ema.europa.eu\/en\/medicines"},{"key":"ioi200111r11","unstructured":"National Institute for Health and Care Excellence website. Accessed January 31, 2020. https:\/\/www.nice.org.uk\/"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2776284\/jamainternal_cherla_2021_oi_200111_1617393555.60756.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T11:04:18Z","timestamp":1617620658000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2776284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.8441","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}